Clinical Trials for Mesothelioma Patients: Dasatinib (NSC #732517)
Read about a current clinical trial being conducted to study the effects of Dasatinib (NSC #732517) for patients who have been diagnosed with mesothelioma. Please note: this information is provided by Weitz & Luxenberg for informational purposes only.
Dasatinib in Treating Patients With Previously Treated Malignant Mesothelioma
A Phase II Study of Dasatinib (NSC #732517) in Patients With Previously Treated Malignant Mesothelioma
Brief Summary
RATIONALE: Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
PURPOSE: This phase II trial is studying how well Dasatinib works in treating patients with previously treated malignant mesothelioma.
Primary:
• To determine the rate of progression-free survival (PFS) at 24 weeks (or 5.5 months) in patients with malignant mesothelioma treated with Dasatinib.
Secondary
• To determine the response rate (partial response [PR] and complete response [CR]) in patients with malignant mesothelioma treated with Dasatinib.
• To determine the response duration in patients with malignant mesothelioma treated with Dasatinib.
• To describe the overall survival (OS) of patients with malignant mesothelioma treated with Dasatinib.
• To describe the toxicity profile of Dasatinib in patients with malignant mesothelioma.
• To determine whether the amount of expression of EphA2 and PDGFRß, as measured by immunohistochemistry from tumor specimens, correlates with PFS in patients with malignant mesothelioma.
• To determine whether plasma levels of VEGF and PDGFRß, serum levels of CSF-1, and soluble mesothelin-related protein correlate with PFS in patients with malignant mesothelioma.
• To determine whether inhibition of Src phosphorylation in PBMC correlates with PFS.
• To assess inhibition of phosphorylation of Src, EphA2, and PDGFRß in tumor tissue by Dasatinib.
Courtesy of ClinicalTrials.gov,
Other helpful links:
Asbestos Asbestos
Asbestos and lung cancer Asbestos and lung cancer
Mesothelioma attorney Mesothelioma attorney
Mesothelioma Lawyer Mesothelioma lawyer
Asbestos attorney Asbestos attorney
Study description of Cisplatin and Pemetrexed on mesothelioma cancer